Search - tctmd.com

Displaying 421 - 440 of 1387

Sort: Relevancy | Date

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

L.A. McKeown

December 16, 2022

News Daily News

Not Just Hot, but Also Cold Weather Extremes Linked to More CV Deaths

Caitlin E. Cox

December 15, 2022

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

News Daily News

Aortic Aneurysm Killed Soccer Journalist Grant Wahl, Wife Says

L.A. McKeown

December 14, 2022

News Daily News

Global Cardio-Oncology Viewpoints ‘Contextualize’ ESC Guidelines

L.A. McKeown

December 12, 2022

News Daily News

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Michael O'Riordan

December 07, 2022

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

Greater Carotid Plaque Burden in Asthmatic Patients: MESA

Michael O'Riordan

November 24, 2022

News Daily News

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

Todd Neale

November 16, 2022

News Daily News

New Risk Models Superior to Pretest Probability at Predicting CAD

Yael L. Maxwell

November 15, 2022

News Conference News AHA 2022

Sizeable Minority of Pregnant Women Have CVD, US Data Show

Caitlin E. Cox

November 11, 2022

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

News Conference News AHA 2022

China Rural Intervention Still Reaping BP Control Wins at 3 Years

L.A. McKeown

November 09, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

News Conference News AHA 2022

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

Caitlin E. Cox

November 08, 2022

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

Todd Neale

November 05, 2022

Advertisement

Reduction in BP Drives Treatment Preference for Hypertensive Patients

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

Not Just Hot, but Also Cold Weather Extremes Linked to More CV Deaths

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Aortic Aneurysm Killed Soccer Journalist Grant Wahl, Wife Says

Global Cardio-Oncology Viewpoints ‘Contextualize’ ESC Guidelines

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Greater Carotid Plaque Burden in Asthmatic Patients: MESA

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

New Risk Models Superior to Pretest Probability at Predicting CAD

Sizeable Minority of Pregnant Women Have CVD, US Data Show

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

China Rural Intervention Still Reaping BP Control Wins at 3 Years

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content